The aim of this study was to report on diagnoses of melanoma in England between 2016 and 2021 on: (i) the frequency of molecular BRAF testing, including regional variations; (ii) the association of patient and tumour characteristics with BRAF mutations; and (iii) the treatment received and survival of patients with BRAF mutations. This evidence concerns the gene BRAF and melanoma.